Axsome Therapeutics

Valuation Analysis

About the Company

Axsome Therapeutics en bref

Axsome Therapeutics (AXSM) is currently trading at 189,00 € with a market capitalization of 9,7 Md €. The 52-week range spans from 83,31 € to 225,59 €; the current price is 16.2% below the yearly high. Year-over-year revenue growth stands at +57.4%.

💰 Dividende

Axsome Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

21 analystes évaluent Axsome Therapeutics (AXSM) au consensus : Achat Fort. L'objectif de cours moyen est de 244,77 €, soit un potentiel de +29.51% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 209,81 € à 329,46 €.

Axsome Therapeutics : la thèse d'investissement en détail

Axsome Therapeutics (AXSM) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 57.4% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 92.6%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 29.51% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 402.84% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The analyst consensus price target implies 29.51% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (9.2%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Axsome Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.